Clinical Trial Update: Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update reports on the use of dabrafenib and lapatinib in patients with unresectable or metastatic thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• TAFINLAR (DABRAFENIB)
• Tykerb (lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING